Trials / Recruiting
RecruitingNCT07075185
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Kelonia Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
Conditions
- Multiple Myeloma in Relapse
- Myeloma Multiple
- Multiple Myeloma Progression
- Neoplasms by Histologic Type
- Neoplasm
- Hemostatic Disorders
- Vascular Disorder
- Paraproteinemias
- Blood Protein Disorders
- Hematologic Disease and Disorders
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Immune System Disease
- Gene Therapy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KLN-1010 | Given at specified dose one time |
Timeline
- Start date
- 2025-07-16
- Primary completion
- 2027-03-01
- Completion
- 2042-05-01
- First posted
- 2025-07-20
- Last updated
- 2026-04-16
Locations
7 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07075185. Inclusion in this directory is not an endorsement.